The Microbiota-Gut-Brain Axis and Alzheimer's Disease: Neuroinflammation Is to Blame?

Ashwinipriyadarshini Megur1, Daiva Baltriukienė1, Virginija Bukelskienė1

  • 1Life Sciences Center, Department of Biological Models, Institute of Biochemistry, Vilnius University, Sauletekio Ave. 7, LT-10257 Vilnius, Lithuania.

Nutrients
|December 30, 2020
PubMed

Insights

Disturbances in the microbiota-gut-brain axis contribute to Alzheimer's disease (AD) development. Modulating gut microbiota may offer new therapeutic strategies for AD.

Area of Science:

  • Neuroscience
  • Microbiology
  • Gastroenterology

Background:

  • Alzheimer's disease (AD) is a leading cause of dementia.
  • The microbiota-gut-brain (MGB) axis plays a role in brain function and behavior.

Purpose of the Study:

  • To review the contribution of MGB axis disturbances to AD development.
  • To highlight the role of gut dysbiosis in AD pathogenesis.

Main Methods:

  • Review of experimental and clinical data on the MGB axis and AD.
  • Analysis of the impact of gut microbiota alterations on the blood-brain barrier and neuroinflammation.

Main Results:

  • Gut microbiota alterations increase gut permeability and activate immune cells, impairing blood-brain barrier function.
  • Bacterial products like lipopolysaccharides and amyloids trigger neuroinflammation, neuronal loss, and injury.
  • Gut dysbiosis and microbiota-host interactions are implicated in AD.

Conclusions:

  • The MGB axis is a significant factor in AD development.
  • Modulating gut microbiota through antibiotics or probiotics presents potential preventive and therapeutic avenues for AD.
  • Further research into MGB axis involvement is crucial for identifying new AD treatment targets.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.2K
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
683
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
590
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.1K